Enrico Maffini, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Matthias Stelljes, Thomas Schroeder, Herman Einsele, Johanna Tischer, Martin Bornhäuser, Wolfgang Bethge, Arne Brecht, Wolf Rösler, Peter Dreger, Kerstin Schäfer-Eckart, Jakob Passweg, Igor Wolfgang Blau, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Older adults with acute myeloid leukemia (AML) refractory to initial or reinduction chemotherapy have a dismal prognosis if they do not undergo hematopoietic stem-cell transplantation (HCT). However, data assessing HCT outcomes from different donors are scarce. We evaluated results from a retrospective analysis on patients aged ≥70 years, with AML not in remission who received an allogeneic HCT from HLA-matched sibling donor (MSD), HLA-10/10 matched unrelated donor (MUD), or T-cell replete haploidentical (Haplo) donor, from 2010 to 2021, reported to the ALWP-EBMT database...
March 30, 2024: Bone Marrow Transplantation